Recombinant Human hCD83 Protein

Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.

N-terminal histidine tag

-20°C

Recombinant Human hCD83, derived from the transfected human HEK293 cells.

CD83

Lyophilized from a 0.2 µm filtered solution in PBS

hCD83, CD83 antigen, hCD83, B-cell activation protein, Cell surface protein HB15, CD83 Molecule, CD83 Antigen (Activated B Lymphocytes, Immunoglobulin Superfamily), Cell-Surface Glycoprotein, BL11, HB15

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1.0 mg/mL with sterile deionized water.

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: Protein standard ladder (kDa).Lane 2: Untreated protein under reducing conditions.Lane 3: Treated protein with deglycosylation enzymes under native conditions.Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.Lane 5: Deglycosylation mixture only without target proteins.